OUR SCIENCE
What we develop
Our multidisciplinary team has developed a universal and extremely immunogenic recombinant protein vaccine platform called MultiTEP

To generate relatively high concentrations of antibodies against the pathological molecules involved in AD, we recently developed a unique vaccine platform called MultiTEP for neurodegenerative disorders. This vaccine platform is composed of a string of promiscuous foreign Th epitopes from pathogens plus a synthetic Th epitope, PADRE. The MultiTEP vaccine stimulates adaptive immunity providing a broad coverage of human MHC polymorphisms and activates both naive Th cells and pre-existing memory Th cells generated in response to conventional vaccines and/or infections with various pathogens during one’s lifespan.

In preclinical studies, MultiTEP has proven to be a highly immunogenic vaccine platform for generating high antibody titers in vaccinated mice, rabbits and non-human primates.


B cell-oriented antigen
T cell-oriented antigen
Universal MultiTEP platform
We use three copies of target epitopes for better antibody production.
MultiTEP provides a robust, broad T helper signal and significantly increases antibody production to harmful proteins.

We also in-licensed a novel, highly immunogenic adjuvant to give a super boost to antibody generation.

Adjuvant
The B cell epitopes from disease-related pathological molecules attached to this universal vaccine platform allow us to generate a recombinant protein vaccine producing high titers of therapeutic antibodies.
Based on what we observed in aged non-human primates, we believe MultiTEP may be especially beneficial in elderly people.

01.
Target not only naïve, but also pre-existing memory Th cells specific to pathogens that most adults would have either been exposed to or vaccinated against, and taking advantage of the high levels of memory Th cells overcome immunosenescence in the elderly
Avoid the generation of harmful autoreactive T cells (e.g., specific to self Aβ, tau, α-syn, etc.)
Activate a broad repertoire of Th cells providing broad coverage of the targeted population with high MHC class II gene polymorphism
02.
03.
04.
Alzheimer’s Stages
Nuravax Vaccines
40 — 55 years old
55 — 60 years old
65 — 75 years old
Overcome self-tolerance by activating T helper (Th) cells specific to mixed foreign epitopes incorporated in MultiTEP




Target not only naïve, but also pre-existing memory Th cells specific to pathogens that most adults would have either been exposed to or vaccinated against, and taking advantage of the high levels of memory Th cells overcome immunosenescence in the elderly


Avoid the generation of harmful autoreactive T cells (e.g., specific to self Aβ, tau, α-syn, etc.)





Activate a broad repertoire of Th cells providing broad coverage of the targeted population with high MHC class II gene polymorphism




Preclinical Alzheimer's
Subtle changes in the brain, biomarkers in the cerebrospinal fluid and blood. No memory problems or other symptoms yet.





Mild cognitive impairment
Changes in memory and other cognitive functions, like problem solving and judgment, but not enough to affect daily functioning.




Moderate dementia
Unable to recall a major relevant aspect of their current life, an address or telephone number of many years, or the names of close family members.




Severe dementia
Occasionally forgets the name of the spouse or caregiver on whom he or she is entirely dependent





75 — 85 years old
Our goal is to create a safe, effective vaccine that produces antibody titer levels that are high enough to penetrate the blood-brain barrier to prevent pathological plaques, fibrils and oligomers without negative effects on normal brain activity.
Our treatment strategy is to generate and keep effective and efficient levels of antibodies in the brain that significantly postpone the onset of the disease.
© 2022 Nuravax